|ITCI -- USA Stock|| |
USD 20.80 0.17 0.82%
Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Intra Cellular Therapies is 'Strong Sell'
. Macroaxis provides Intra Cellular buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ITCI positions. The advice algorithm takes into account all of Intra Cellular Thera available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from ITCI buy-and-hold prospective. Please also check Intra Cellular Analyst Recommendation
to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.
For the selected time horizon Intra Cellular Therapies has a mean deviation of 1.92, semi deviation of 2.45, standard deviation of 2.84, variance of 8.06, downside variance of 7.73 and semi variance of 6.0
Macroaxis buy or sell recommendations module can be used to complement current analysts and expert consensus
on Intra Cellular Therapies. Our buy, hold, or sell recommendation engine utilizes analyzes the firm potential to grow using all fundamental data market data available at the time. To make sure Intra Cellular Therapies is not overpriced, please check out all Intra Cellular fundamentals including its Net Income
, Earnings Per Share
, Current Liabilities
, as well as the relationship
between Current Ratio
and Total Asset
. Given that Intra Cellular Thera
has Price to Earning
times, we strongly advise you confirm Intra Cellular Thera market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.
Intra Cellular Thematic Classifications
|BiotechBiotechnology and pharmaceuticals production and services|
Returns Distribution Density
|Mean Return||0.30||Value At Risk||5.15|
|Potential Upside||5.23||Standard Deviation||2.84|
|Security Type||Shares||Value||Rhenman Partners Asset Management Ab||Common Shares||697 K||12.3 M||Franklin Street Advisors Inc||Common Shares||54.1 K||955 K||Essex Investment Management Co Llc||Common Shares||32 K||565 K||Fox Run Management Llc||Common Shares||30.2 K||533 K||Gemmer Asset Management Llc||Common Shares||10 K||177 K||Bank Of Montreal||Common Shares||5.6 K||100 K||Fny Investment Advisers Llc||Common Shares||500||8 K||Fny Investment Advisers Llc||Put Options||5.0||0.0||Dld Asset Management Lp||Call Options||1 M||21.5 M|
Intra Cellular Greeks
Intra Cellular Volatility Alert
Intra Cellular Therapies currently demonstrates below average downside deviation of 2.78. It has Information Ratio of 0.06 and Jensen Alpha of 0.59. However, we do advice investors to further question Intra Cellular Therapies expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.
Intra Cellular Fundamental Vs Peers
| ||Intra Cellular exotic insider transaction detected [view details]|